S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
NASDAQ:SYRS

Syros Pharmaceuticals - SYRS Stock Forecast, Price & News

$2.81
-0.02 (-0.71%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.75
▼
$2.95
50-Day Range
$2.71
▼
$5.32
52-Week Range
$2.67
▼
$14.30
Volume
78,578 shs
Average Volume
140,218 shs
Market Capitalization
$57.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

Syros Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,067.3% Upside
$32.80 Price Target
Short Interest
Healthy
3.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.89
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($4.41) to ($4.60) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

298th out of 986 stocks

Pharmaceutical Preparations Industry

129th out of 477 stocks

See Top Rated MarketRank™ Stocks Here

SYRS stock logo

About Syros Pharmaceuticals (NASDAQ:SYRS) Stock

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Receive SYRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SYRS Stock News Headlines

March 16, 2023 | americanbankingnews.com
Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com
March 6, 2023 | finance.yahoo.com
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2022 Earnings Call Transcript
March 23, 2023 | Investing Daily (Ad)
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
March 5, 2023 | benzinga.com
Syros Pharmaceuticals Stock (NASDAQ:SYRS), Guidance and Forecast
March 4, 2023 | seekingalpha.com
Syros Pharmaceuticals, Inc. (SYRS) Q4 2022 Earnings Call Transcript
March 4, 2023 | finance.yahoo.com
Syros Pharmaceuticals Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag
March 2, 2023 | finance.yahoo.com
Q4 2022 Syros Pharmaceuticals Inc Earnings Call
March 2, 2023 | finance.yahoo.com
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
March 23, 2023 | Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
March 1, 2023 | msn.com
Syros Pharmaceuticals's Earnings Outlook
February 23, 2023 | finance.yahoo.com
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023
January 26, 2023 | markets.businessinsider.com
Syros Gets Fast Track Designation In U.S. For Tamibarotene For Myelodysplastic Syndrome Treatment
January 26, 2023 | msn.com
Syros stock rises as tamibarotene gets FDA fast track status for rare blood cancer
January 26, 2023 | finance.yahoo.com
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
January 24, 2023 | seekingalpha.com
SYRS Syros Pharmaceuticals, Inc.
January 9, 2023 | finance.yahoo.com
Syros Announces Clinical Updates and 2023 Strategic Priorities
January 5, 2023 | markets.businessinsider.com
Analyst Expectations for Syros Pharmaceuticals's Future
December 23, 2022 | msn.com
Syros Pharmaceuticals's Return On Capital Employed Overview
December 16, 2022 | finance.yahoo.com
One Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) insider upped their stake by 212% in the previous year
December 12, 2022 | finance.yahoo.com
Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS
December 10, 2022 | finance.yahoo.com
Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial
December 5, 2022 | finance.yahoo.com
Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10
November 22, 2022 | finance.yahoo.com
Syros to Participate at Piper Sandler 34th Annual Healthcare Conference
November 14, 2022 | finance.yahoo.com
Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Misses Revenue Estimates
November 14, 2022 | finance.yahoo.com
Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
November 8, 2022 | nasdaq.com
Syros Pharmaceuticals Stock (NASDAQ:SYRS): Worse than a Powerball Lottery Ticket?
November 7, 2022 | finance.yahoo.com
Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
See More Headlines
Receive SYRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SYRS Company Calendar

Last Earnings
3/02/2023
Today
3/23/2023
Next Earnings (Estimated)
5/15/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SYRS
CUSIP
N/A
CIK
1556263
Web
www.syros.com
Phone
(617) 744-1340
Fax
N/A
Employees
124
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$32.80
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+471.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($12.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-94,650,000.00
Net Margins
-485.12%
Pretax Margin
-636.12%
Return on Equity
-134.48%
Return on Assets
-58.40%

Debt

Debt-to-Equity Ratio
0.32
Current Ratio
6.87
Quick Ratio
6.87

Sales & Book Value

Annual Sales
$14.88 million
Price / Sales
3.82
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.32 per share
Price / Book
0.44

Miscellaneous

Outstanding Shares
20,300,000
Free Float
17,704,000
Market Cap
$56.84 million
Optionable
Optionable
Beta
1.66

Key Executives

  • Nancy A. Simonian
    President, Chief Executive Officer & Director
  • Jason Haas
    Chief Financial Officer
  • Eric R. OlsonEric R. Olson
    Chief Scientific Officer
  • David A. Roth
    Chief Medical Officer
  • Conley Chee
    Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SYRS Stock - Frequently Asked Questions

Should I buy or sell Syros Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SYRS shares.
View SYRS analyst ratings or view top-rated stocks.

What is Syros Pharmaceuticals' stock price forecast for 2023?

5 brokerages have issued 12-month target prices for Syros Pharmaceuticals' stock. Their SYRS share price forecasts range from $13.00 to $100.00. On average, they expect the company's stock price to reach $32.80 in the next twelve months. This suggests a possible upside of 1,071.4% from the stock's current price.
View analysts price targets for SYRS or view top-rated stocks among Wall Street analysts.

How have SYRS shares performed in 2023?

Syros Pharmaceuticals' stock was trading at $3.59 on January 1st, 2023. Since then, SYRS shares have decreased by 22.0% and is now trading at $2.80.
View the best growth stocks for 2023 here.

When is Syros Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our SYRS earnings forecast.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) posted its earnings results on Thursday, March, 2nd. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by $0.01. The firm had revenue of ($0.75) million for the quarter, compared to analyst estimates of $3.28 million. Syros Pharmaceuticals had a negative net margin of 485.12% and a negative trailing twelve-month return on equity of 134.48%.

When did Syros Pharmaceuticals' stock split?

Syros Pharmaceuticals's stock reverse split before market open on Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Millennium Management LLC (0.45%), Renaissance Technologies LLC (0.23%), LPL Financial LLC (0.20%), ExodusPoint Capital Management LP (0.17%), Jane Street Group LLC (0.08%) and HighTower Advisors LLC (0.07%). Insiders that own company stock include Eric R Olson, Eric R Olson, Mark J Alles, Richard A Young, Srinivas Akkaraju and Timothy Tyson.
View institutional ownership trends.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $2.80.

How much money does Syros Pharmaceuticals make?

Syros Pharmaceuticals (NASDAQ:SYRS) has a market capitalization of $56.84 million and generates $14.88 million in revenue each year. The company earns $-94,650,000.00 in net income (profit) each year or ($12.78) on an earnings per share basis.

How many employees does Syros Pharmaceuticals have?

The company employs 124 workers across the globe.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The official website for the company is www.syros.com. The company can be reached via phone at (617) 744-1340 or via email at hannahd@sternir.com.

This page (NASDAQ:SYRS) was last updated on 3/23/2023 by MarketBeat.com Staff